Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001018833 | SCV001180115 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-09-29 | criteria provided, single submitter | clinical testing | The c.3151_3152dupGT pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a duplication of GT at nucleotide position 3151, causing a predicted alternate stop codon (p.E1052*). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001860929 | SCV002203245 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2023-08-30 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 823006). This variant has not been reported in the literature in individuals affected with MSH6-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu1052*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). |
Myriad Genetics, |
RCV003455102 | SCV004185722 | pathogenic | Lynch syndrome 5 | 2023-08-22 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Baylor Genetics | RCV003461374 | SCV004196383 | likely pathogenic | Endometrial carcinoma | 2021-02-09 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001355629 | SCV001550565 | uncertain significance | Carcinoma of colon | no assertion criteria provided | clinical testing |